With revenues of €213 million1 in 2016 and a record of vigorous growth, Chiesi Ltd. aspires to be the largest affiliate in the Chiesi group – and as outright winners of the company’s Operational Excellence Award 2015, it is clear we aim to be the best!
In the UK, Chiesi Ltd. employs c.252 dedicated employees, who are based out of our new head office in Manchester, the Research and Development centres in Chippenham and Oxford, or are part of our experienced field-based sales teams.
As with every part of the Chiesi group, we embrace a shared set of values and a common code of ethical conduct. This demands the highest standards of reliability, transparency, and individual accountability, in everything we do. It emphasises the importance of collaborative working, putting people first and exchanging knowledge. Implicit in all of these values is a responsible attitude to the social and environmental impact of our actions.
As we enter important new therapy areas, such as organ transplantation and rare diseases, alongside our treatments for respiratory conditions, Chiesi Ltd. is poised to extend further still the contribution we make to public health in the UK. As the winners of an independent Top Employer Award in the UK and Europe for the fourth consecutive year, ours is a culture where innovation and professional excellence flourish.
Chiesi Farmaceutici S.p.A. is an international, privately-owned pharmaceutical company, based in Parma, Italy. Chiesi is dedicated to the research, development and sales of innovative, therapeutic prescription medicines in the field of respiratory, neonatology, transplant medicine and rare diseases.
The Company was founded in 1935, as a family firm. Chiesi spans the globe, employing more than 4,800 people in 26 affiliates worldwide and sells its products in more than 70 countries. 2
We embrace innovation which is a constant driver to our continued success. Products wholly, or partially, developed by Chiesi account for three quarters of our sales2, and our investment in Research and Development currently stands at a record €340 million - 21% of our revenue. Chiesi ‘firsts’ include the first stem cell product approved in Europe and new options for serious genetic diseases. We applied for 16 new patents in 2016 alone. 1
Chiesi Ltd. was established in 1999 with the acquisition of Trinity Pharmaceuticals (by Chiesi S.p.A), whose ethos, values and specialist expertise perfectly complemented those that underpin the wider Chiesi group.